Cargando…
New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management
PURPOSE OF REVIEW: Oncological treatments are known to induce cardiac toxicity, but the impact of new-onset cancer in patients with pre-existing HF remains unknown. This review focuses on the epidemiology, pathophysiological mechanisms, and clinical implications of HF patients who develop malignanci...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342372/ https://www.ncbi.nlm.nih.gov/pubmed/34181210 http://dx.doi.org/10.1007/s11897-021-00517-y |
_version_ | 1783734054403702784 |
---|---|
author | Cuomo, Alessandra Paudice, Francesca D’Angelo, Giovanni Perrotta, Giovanni Carannante, Antonio Attanasio, Umberto Iengo, Martina Fiore, Francesco Tocchetti, Carlo Gabriele Mercurio, Valentina Pirozzi, Flora |
author_facet | Cuomo, Alessandra Paudice, Francesca D’Angelo, Giovanni Perrotta, Giovanni Carannante, Antonio Attanasio, Umberto Iengo, Martina Fiore, Francesco Tocchetti, Carlo Gabriele Mercurio, Valentina Pirozzi, Flora |
author_sort | Cuomo, Alessandra |
collection | PubMed |
description | PURPOSE OF REVIEW: Oncological treatments are known to induce cardiac toxicity, but the impact of new-onset cancer in patients with pre-existing HF remains unknown. This review focuses on the epidemiology, pathophysiological mechanisms, and clinical implications of HF patients who develop malignancies. RECENT FINDINGS: Novel findings suggest that HF and cancer, beside common risk factors, are deeply linked by shared pathophysiological mechanisms. In particular, HF itself may enhance carcinogenesis by producing pro-inflammatory cytokines, and it has been suggested that neurohormonal activation, commonly associated with the failing heart, might play a pivotal role in promoting neoplastic transformation. SUMMARY: The risk of malignancies seems to be higher in HF patients compared to the general population, probably due to shared risk factors and common pathophysiological pathways. Additionally, management of these patients represents a challenge for clinicians, considering that the co-existence of these diseases significantly worsens patients’ prognosis and negatively affects therapeutic options for both diseases. |
format | Online Article Text |
id | pubmed-8342372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-83423722021-08-20 New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management Cuomo, Alessandra Paudice, Francesca D’Angelo, Giovanni Perrotta, Giovanni Carannante, Antonio Attanasio, Umberto Iengo, Martina Fiore, Francesco Tocchetti, Carlo Gabriele Mercurio, Valentina Pirozzi, Flora Curr Heart Fail Rep Translational Research in Heart Failure (E. Bertero, Section Editor) PURPOSE OF REVIEW: Oncological treatments are known to induce cardiac toxicity, but the impact of new-onset cancer in patients with pre-existing HF remains unknown. This review focuses on the epidemiology, pathophysiological mechanisms, and clinical implications of HF patients who develop malignancies. RECENT FINDINGS: Novel findings suggest that HF and cancer, beside common risk factors, are deeply linked by shared pathophysiological mechanisms. In particular, HF itself may enhance carcinogenesis by producing pro-inflammatory cytokines, and it has been suggested that neurohormonal activation, commonly associated with the failing heart, might play a pivotal role in promoting neoplastic transformation. SUMMARY: The risk of malignancies seems to be higher in HF patients compared to the general population, probably due to shared risk factors and common pathophysiological pathways. Additionally, management of these patients represents a challenge for clinicians, considering that the co-existence of these diseases significantly worsens patients’ prognosis and negatively affects therapeutic options for both diseases. Springer US 2021-06-28 2021 /pmc/articles/PMC8342372/ /pubmed/34181210 http://dx.doi.org/10.1007/s11897-021-00517-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Translational Research in Heart Failure (E. Bertero, Section Editor) Cuomo, Alessandra Paudice, Francesca D’Angelo, Giovanni Perrotta, Giovanni Carannante, Antonio Attanasio, Umberto Iengo, Martina Fiore, Francesco Tocchetti, Carlo Gabriele Mercurio, Valentina Pirozzi, Flora New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management |
title | New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management |
title_full | New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management |
title_fullStr | New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management |
title_full_unstemmed | New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management |
title_short | New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management |
title_sort | new-onset cancer in the hf population: epidemiology, pathophysiology, and clinical management |
topic | Translational Research in Heart Failure (E. Bertero, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342372/ https://www.ncbi.nlm.nih.gov/pubmed/34181210 http://dx.doi.org/10.1007/s11897-021-00517-y |
work_keys_str_mv | AT cuomoalessandra newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT paudicefrancesca newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT dangelogiovanni newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT perrottagiovanni newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT carannanteantonio newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT attanasioumberto newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT iengomartina newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT fiorefrancesco newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT tocchetticarlogabriele newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT mercuriovalentina newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement AT pirozziflora newonsetcancerinthehfpopulationepidemiologypathophysiologyandclinicalmanagement |